Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinomaXuejun Xu(Baylor College of Medicine), Donglai Chen(Wenzhou University)Cancer MedicineMarch 6, 202310.1002/cam4.5731Cited by 14SaveCiteExport RISWatch citationsRelated PapersChemical Probes that Competitively and Selectively Inhibit Stat3 Activation|PLoS ONE|2009|129Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway|Frontiers in Pharmacology|2018|48